Yale Secret Shopper Audit Finds 49 Telehealth Sites Issue GLP-1 Scripts After Minimal Screening

The Yale secret-shopper audit documented that 39 of 49 sites approved semaglutide or tirzepatide within minutes of an online form that rarely requested recent HbA1c, thyroid function, or history of medullary thyroid carcinoma. Only six sites required video verification of identity or vital signs; three explicitly offered compounded versions despite FDA shortage warnings. Average time from submission to prescription was under 15 minutes, with monthly prices ranging $199-$299 without insurance adjudication.

This pattern aligns with prior telehealth expansions during the 2022-2024 semaglutide shortage, when FDA compounding guidance was temporarily relaxed. Observational claims data from 2023-2025 show a 340% rise in new GLP-1 starts via telehealth, yet gastrointestinal adverse-event reports and discontinuation rates within 90 days remain elevated compared with endocrinology clinic cohorts. Minimal oversight also bypasses required counseling on pancreatitis and gallbladder risk.

Compounded GLP-1 products lack bioequivalence testing required for approved drugs, raising dosing variability concerns documented in FDA adverse-event databases. The JAMA findings coincide with state medical-board actions in California and New York that have begun fining platforms for failing to meet controlled-substance prescribing standards.

Next regulatory steps include possible DEA scheduling review of semaglutide and stricter REMS-like requirements for telehealth platforms; enforcement data through Q4 2026 will indicate whether oversight tightens or remains fragmented across jurisdictions.